Recursion Pharmaceuticals, Inc.
3.44
-1.43% (최근 종가 3.49)
Company profile — from Yahoo Finance
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Company information as provided by Yahoo Finance. Check the official filings before relying on it.
Market Cap
19억 달러
PER
-
Trailing 12 months
Forward P/E
-4.0배
Forward estimates
ROE
-56.6%
Return on equity
Dividend Yield
-
Beta
1.05
Volatility vs market
52주 범위에서 15% 지점입니다. 100%에 가까울수록 1년 최고가 부근입니다.
Source: Yahoo Finance
Average analyst price target
범위 $4.00 ~ $10.00 · 애널리스트 6명 · 종합의견 매수 · 출처 Yahoo Finance
Analyst rating breakdown (2026-08-01)
월가는 이 종목을 뚜렷한 매수 우위로 보고 있습니다. (매수 8 · 관망 5 · 매도 0)
Revenue trend
1억 달러
2022–2025 회계연도 · 축 단위는 달러입니다.
Net income trend
-6억 달러
2022–2025 회계연도 · 축 단위는 달러입니다.
| Year | Revenue | Operating Income | Net Income | Operating Cash Flow | Net Margin |
|---|---|---|---|---|---|
| 2025 | 1억 달러 | -6억 달러 | -6억 달러 | -4억 달러 | -868.3% |
| 2024 | 1억 달러 | -5억 달러 | -5억 달러 | -4억 달러 | -792.7% |
| 2023 | 0억 달러 | -4억 달러 | -3억 달러 | -3억 달러 | -747.7% |
| 2022 | 0억 달러 | -2억 달러 | -2억 달러 | -1억 달러 | -603.5% |
회계연도 기준 실적입니다(달력 연도와 다를 수 있습니다). 출처: Yahoo Finance. 값이 없는 항목은 채우지 않고 "-"로 둡니다.
SeekingAlpha · 08. 20.
Benzinga · 08. 20.
Prices, key stats, price targets, annual financials, filings and news above come straight from Yahoo Finance · Finnhub · SEC EDGAR, so they look the same for any US-listed ticker.
Support & resistance shows above whenever my TradingView indicator is sending alerts for the ticker. No alert is set up for this one yet, so there are no levels.
Option levels · MJM Score · REAL_BUY signals come through a Google Sheet and are still limited to the fixed watchlist. We leave them out rather than guess.
